Developer docs
API playgroundTry for free, no card

Search company profiles

Nome Bio

Full company profile

uuid00svrct

Namestring
Nome Bio
Legal namestring
Nome Therapeutics Inc.
Websiteurl
nome.bio
Company typeenum
Private
Founded yearint
2025
Descriptiontext

Nome Bio (legal entity Nome Therapeutics Inc.) is a Delaware-incorporated, San Diego-based services company that develops and coordinates personalized genetic therapies for patients with rare inherited diseases. The company operates an AI platform combined with human expert review that evaluates a patient's specific genetic mutation against every available therapeutic modality in parallel — antisense oligonucleotides, gene therapy, gene editing, and drug repurposing — to identify the fastest viable path to a custom treatment. Core product offerings include a free Initial Assessment Report (AI-generated, expert-reviewed), a Provider Brief for clinicians with an interrogable chat interface, and an Action Plan covering execution-ready next steps.

Underlying technology includes a multi-modality parallel evaluation engine, generative AI models trained on prior INDs, FDA guidance, and IRB precedent that produce first-draft regulatory submissions with citations, and an AI-driven program orchestration layer coordinating work across 30+ pre-contracted fee-for-service vendors (CROs, CDMOs, manufacturers, regulatory consultants). All work product and IP are structured to remain with the patient family or foundation from day one.

The revenue model is freemium at the top of funnel (free initial genetic assessment) converting into fee-for-service multi-year therapeutic development programs priced per engagement, with no royalties or equity taken from families. Distribution is hybrid: a self-serve digital intake (Typeform) for patients, a gated HIPAA-compliant Provider Platform for clinicians, and referral partnerships with patient advocacy foundations. The company serves rare disease patients and families (primary), clinicians at academic medical centers, research labs and patient foundations, and pharmaceutical companies seeking validation of platform treatment opportunities. Operations are currently domestic-only (United States).

Short descriptiontext

Nome Bio operates an AI platform with human expert review that develops and coordinates personalized genetic therapies for rare disease patients, families, and clinicians across ASO, gene therapy, gene editing, and drug repurposing modalities.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
personalized genetic therapy, rare disease therapeutics, genetic medicine development, n-of-1 therapies, AI drug development
Industry4 codes
PRIMARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLAGAFAN
Nonclinical Study Management & Regulatory Writing (IND-enabling)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code3 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medical Laboratories621511
SIC code2 codes
  • Services-Health Services8000
  • Services-Medical Laboratories8071
Product category
Personalized Genetic Medicine Services
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Free Initial Genetic Assessment
TypeFreemium
Description

Nome provides a free initial evaluation report analyzing whether a personalized genetic therapy might be appropriate for the patient's specific mutation. This drives top-of-funnel engagement and qualification.

nome.bio
2Fee-for-Service Therapeutic Development Programs
TypeProfessional Services
Description

For families and organizations that proceed after the free evaluation, Nome charges transparent fees for developing comprehensive therapeutic plans and managing the full development process, including selecting partners, coordinating manufacturing, and navigating FDA pathways. The service is priced as a fee-for-service model with no royalties or equity taken from families, and IP is held by the patient/family from day zero.

nome.bio
3Provider Platform Access
TypeSubscription Recurring
Description

Clinicians register and access the platform to receive Provider Briefs for their patients. While the initial evaluation is free for patients, clinicians at health systems may pay for platform access or the service is structured as a referral/coordinated care model.

nome.bio
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details2 tiers
1Free initial genetic evaluation
ModelFreemiumBilling cadencePay-as-you-go
Notes

Share your genetic data; receive a free AI-generated, expert-reviewed report on whether a custom therapy might be appropriate for your condition. No cost, no obligation to proceed.

nome.bio
2Therapeutic plan and development program
ModelOtherBilling cadenceMulti-year contract
Notes

Transparent pricing for services to develop a therapeutic plan and manage the full program. Exact price not publicly listed; quote-based. Nome works with families to find financial solutions. Note: a representative cost of ~$800,000 is cited for manufacturing a custom gene editing therapy (Baby KJ case), though Nome's fees cover program coordination rather than direct manufacturing costs.

nome.bio
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Core offering1 text field

Nome provides genetic medicine development as a service for rare disease families, patient foundations, and health systems. Using an AI platform combined with human expert review, the company delivers a free Initial Assessment Report evaluating personalized therapy options for a patient's specific mutation, a clinician-facing Provider Brief with mechanism-level rationale, and end-to-end Therapeutic Development Programs that coordinate 30+ vendors across the full lifecycle from diagnosis through FDA pathways to clinical execution. Programs are structured as fee-for-service with no royalties or equity taken from families, and IP is held by the patient or family from day one.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Free initial evaluation delivered within 1-2 weeks of receiving genetic diagnosis
+3 more records
Product overview1 text field

Nome is a services company operating the Operating System for Personalized Therapeutics™ — a unified platform combining an AI analysis engine with human expert oversight. The core offering includes an Initial Assessment Report (AI-generated, expert-reviewed free evaluation of therapy options), a Provider Brief (prioritized options with citations for clinicians), and an Action Plan (detailed execution steps). The platform serves rare disease patients, foundations, health systems, and clinicians by coordinating the full lifecycle of therapeutic development across multiple modalities including gene therapy, ASO therapy, and gene editing.

Product and service3 records
1Personalized Therapy Development Program
CategoryTherapeutic Development Services
Description

End-to-end fee-for-service engagement in which Nome's AI platform and human experts evaluate a patient's specific mutation across multiple therapeutic modalities (ASO, gene therapy, gene editing, drug repurposing), select the fastest viable path, and coordinate 30+ vetted vendors (manufacturers, CROs, CDMOs, regulatory consultants) to develop and deliver a personalized therapy. Programs are priced transparently with no royalties or equity taken from families; all IP is held by the patient or family entity from day one. A comprehensive therapeutic plan is developed within 30 days of the initial assessment.

2Provider Platform (HIPAA-Compliant Clinician Portal)
CategoryClinical Decision Support Platform
Description

Secure, gated web platform for clinicians at academic medical centers, geneticists, and rare disease specialists to submit patient genetic data under a HIPAA Business Associate Agreement and receive a prioritized Provider Brief with mechanism-level rationale, peer-reviewed citations, and an interrogable chat interface to explore how recommendations were generated.

3Initial Genetic Assessment Report
CategoryGenetic Evaluation Service
Description

Free initial evaluation service for rare disease patients and families. After submitting a genetic diagnosis through Nome's online intake (Typeform), recipients receive an AI-generated, expert-reviewed report within 1-2 weeks assessing whether a personalized genetic therapy may be appropriate for their specific mutation across multiple modalities. No cost and no obligation to proceed.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

COMBINEDBrain is a nonprofit consortium representing 65+ rare genetic neurodevelopmental disorder advocacy groups, operating a centralized biorepository in partnership with IBX. Nome works with COMBINEDBrain's biorepository network to ensure patient samples are banked, tracked, and available for downstream therapeutic development. The partnership enables patient cell banking logistics as part of Nome's program management.

230+ Fee-for-Service Vendors
Strategic tierCoreTypeOthers
Description

Nome operates a network of more than 30 fee-for-service vendors including contract manufacturers, CROs, CDMOs, analytics providers, and regulatory consultants. All contracts are structured fee-for-service with right of reference and escrow provisions, ensuring families/patient entities own all work product and can switch operators without regulatory restart.

nome.bio
3Kizuna Foundation
Strategic tierCoreTypeStrategic or Co-development Partner
Description

The founder Stevie Ringel founded the Kizuna Foundation (a 501(c)(3)) to develop a novel gene therapy for his own rare retinal disease before starting Nome. The foundation's work informs Nome's model and the KIZ-mutation retinitis pigmentosa gene therapy program represents an early proof case for Nome's evaluation approach.

nome.bio
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Winston Yan, President of the N=1 Collaborative, serves as an advisor to Nome. The N=1 Collaborative (past 2,000 members) is a key organization advancing individualized ASO and gene therapy. This advisory relationship connects Nome to the broader N-of-1 therapy ecosystem.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Tempus AI
TypeBroad incumbent
Description

AI-powered precision medicine company with extensive multimodal data, sequencing, and clinical decision support capabilities. Overlapping AI-health positioning with much broader scale and enterprise contracts across pharma and providers.

TypeBroad incumbent
Description

Clinical genomics company focused on rare disease diagnosis and whole exome/genome sequencing. Operates upstream of Nome's workflow — feeds the genetic diagnoses that create Nome's customer pipeline — and represents a potential strategic partner or channel.

TypeEmerging player
Description

AI company designing AAV capsid delivery vectors for gene therapy, including brain-targeting variants. Referenced in Nome's content; operates as a delivery-technology enabler that could integrate into Nome-coordinated programs.

TypeBroad incumbent
Description

AI-native drug discovery company combining high-throughput biology with machine learning to identify treatments across multiple disease areas. Comparable AI-for-drug-discovery positioning, but operates a broad pipeline model rather than individualized therapy services.

TypeDirect peer
Description

Nonprofit consortium representing 65+ rare genetic neurodevelopmental disorder advocacy groups and operating a centralized biorepository. Both strategic partner and peer — overlapping patient access mission in the rare pediatric neurodevelopmental space, with biorepository and cell-banking infrastructure Nome relies on.

TypeEmerging player
Description

AI-driven oligonucleotide therapeutics company engineering ASOs and siRNAs with safety/efficacy predictively modeled. Comparable AI + genetic medicine focus at the modality level; could be a vendor or partner within Nome's ecosystem.

TypeBroad incumbent
Description

Large CRO/CDMO providing preclinical, clinical, and manufacturing services to the rare disease and broader biotech market. Comparable as one of the vendor types Nome orchestrates; could plausibly build or acquire an n-of-1 coordination layer.

TypeDirect peer
Description

Mission-driven organization advancing individualized ASO and gene therapy development, with 2,000+ members across the n-of-1 ecosystem. Directly comparable mission; an advisor to Nome sits on its leadership. Operates as a community/research consortium rather than a commercial service.

TypeBroad incumbent
Description

AI-driven RNA therapeutics company using machine learning to identify novel genetic medicines. Comparable AI + genetic medicine positioning, but a pipeline-based biotech rather than a service platform; an advisor (former SVP Research Operations) previously worked there.

TypeDirect peer
Description

Nonprofit providing individualized antisense oligonucleotide (ASO) therapies to patients with ultra-rare genetic diseases at no cost. Most direct peer — also a free, individualized genetic therapy access program for n-of-1 patients, though non-commercial and ASO-only versus Nome's multi-modality commercial model.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nome Bio

Personalized Genetic Medicine Servicesnome.bio

Nome Bio operates an AI platform with human expert review that develops and coordinates personalized genetic therapies for rare disease patients, families, and clinicians across ASO, gene therapy, gene editing, and drug repurposing modalities.

What Nome Bio does

Nome Bio (legal entity Nome Therapeutics Inc.) is a Delaware-incorporated, San Diego-based services company that develops and coordinates personalized genetic therapies for patients with rare inherited diseases. The company operates an AI platform combined with human expert review that evaluates a patient's specific genetic mutation against every available therapeutic modality in parallel — antisense oligonucleotides, gene therapy, gene editing, and drug repurposing — to identify the fastest viable path to a custom treatment. Core product offerings include a free Initial Assessment Report (AI-generated, expert-reviewed), a Provider Brief for clinicians with an interrogable chat interface, and an Action Plan covering execution-ready next steps.

Underlying technology includes a multi-modality parallel evaluation engine, generative AI models trained on prior INDs, FDA guidance, and IRB precedent that produce first-draft regulatory submissions with citations, and an AI-driven program orchestration layer coordinating work across 30+ pre-contracted fee-for-service vendors (CROs, CDMOs, manufacturers, regulatory consultants). All work product and IP are structured to remain with the patient family or foundation from day one.

The revenue model is freemium at the top of funnel (free initial genetic assessment) converting into fee-for-service multi-year therapeutic development programs priced per engagement, with no royalties or equity taken from families. Distribution is hybrid: a self-serve digital intake (Typeform) for patients, a gated HIPAA-compliant Provider Platform for clinicians, and referral partnerships with patient advocacy foundations. The company serves rare disease patients and families (primary), clinicians at academic medical centers, research labs and patient foundations, and pharmaceutical companies seeking validation of platform treatment opportunities. Operations are currently domestic-only (United States).

Nome Bio firmographics

Firmographics
Name
Nome Bio
Legal name
Nome Therapeutics Inc.
Website
https://nome.bio
Company type
Private
Founded year
2025
Operating status
Operating
Headcount range
1–10 employees
Short description
Nome Bio operates an AI platform with human expert review that develops and coordinates personalized genetic therapies for rare disease patients, families, and clinicians across ASO, gene therapy, gene editing, and drug repurposing modalities.
Ownership category
akta.pro rank

Nome Bio industry classification

Industry
Product category
Personalized Genetic Medicine Services
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511)
SIC
Services-Health Services (8000), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLAGAFAN
Nonclinical Study Management & Regulatory Writing (IND-enabling)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Personalized genetic therapy
  • Rare disease therapeutics
  • Genetic medicine development
  • N-of-1 therapies
  • AI drug development

Where Nome Bio is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Nome Bio business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Free Initial Genetic Assessment: Nome provides a free initial evaluation report analyzing whether a personalized genetic therapy might be appropriate for the patient's specific mutation. This drives top-of-funnel engagement and qualification.
  2. Fee-for-Service Therapeutic Development Programs: For families and organizations that proceed after the free evaluation, Nome charges transparent fees for developing comprehensive therapeutic plans and managing the full development process, including selecting partners, coordinating manufacturing, and navigating FDA pathways. The service is priced as a fee-for-service model with no royalties or equity taken from families, and IP is held by the patient/family from day zero.
  3. Provider Platform Access: Clinicians register and access the platform to receive Provider Briefs for their patients. While the initial evaluation is free for patients, clinicians at health systems may pay for platform access or the service is structured as a referral/coordinated care model.

Pricing tiers

ModelBillingPrice
FreemiumPay-as-you-goFree initial genetic evaluation
OtherMulti-year contractTherapeutic plan and development program

Go-to-market motion3 records

Distribution channels3 records

Marketing channels7 records

Nome Bio product offering

Product offering

Core offering

Nome provides genetic medicine development as a service for rare disease families, patient foundations, and health systems. Using an AI platform combined with human expert review, the company delivers a free Initial Assessment Report evaluating personalized therapy options for a patient's specific mutation, a clinician-facing Provider Brief with mechanism-level rationale, and end-to-end Therapeutic Development Programs that coordinate 30+ vendors across the full lifecycle from diagnosis through FDA pathways to clinical execution. Programs are structured as fee-for-service with no royalties or equity taken from families, and IP is held by the patient or family from day one.

Product overview

Nome is a services company operating the Operating System for Personalized Therapeutics™ — a unified platform combining an AI analysis engine with human expert oversight. The core offering includes an Initial Assessment Report (AI-generated, expert-reviewed free evaluation of therapy options), a Provider Brief (prioritized options with citations for clinicians), and an Action Plan (detailed execution steps). The platform serves rare disease patients, foundations, health systems, and clinicians by coordinating the full lifecycle of therapeutic development across multiple modalities including gene therapy, ASO therapy, and gene editing.

Differentiator

Problem solved

Functional benefit

Products and services

  • Personalized Therapy Development Program End-to-end fee-for-service engagement in which Nome's AI platform and human experts evaluate a patient's specific mutation across multiple therapeutic modalities (ASO, gene therapy, gene editing, drug repurposing), select the fastest viable path, and coordinate 30+ vetted vendors (manufacturers, CROs, CDMOs, regulatory consultants) to develop and deliver a personalized therapy. Programs are priced transparently with no royalties or equity taken from families; all IP is held by the patient or family entity from day one. A comprehensive therapeutic plan is developed within 30 days of the initial assessment.
  • Provider Platform (HIPAA-Compliant Clinician Portal) Secure, gated web platform for clinicians at academic medical centers, geneticists, and rare disease specialists to submit patient genetic data under a HIPAA Business Associate Agreement and receive a prioritized Provider Brief with mechanism-level rationale, peer-reviewed citations, and an interrogable chat interface to explore how recommendations were generated.
  • Initial Genetic Assessment Report Free initial evaluation service for rare disease patients and families. After submitting a genetic diagnosis through Nome's online intake (Typeform), recipients receive an AI-generated, expert-reviewed report within 1-2 weeks assessing whether a personalized genetic therapy may be appropriate for their specific mutation across multiple modalities. No cost and no obligation to proceed.

Quantifiable outcome

  • Free initial evaluation delivered within 1-2 weeks of receiving genetic diagnosis
  • +3 more outcomes

Companies that use Nome Bio

Customer profile

Segments4 records

Ideal customer profiles4 records

Nome Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature5 records

Nome Bio partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • COMBINEDBraincoreStrategic or Co-development PartnerCOMBINEDBrain is a nonprofit consortium representing 65+ rare genetic neurodevelopmental disorder advocacy groups, operating a centralized biorepository in partnership with IBX. Nome works with COMBINEDBrain's biorepository network to ensure patient samples are banked, tracked, and available for downstream therapeutic development. The partnership enables patient cell banking logistics as part of Nome's program management.
  • 30+ Fee-for-Service VendorscoreOthersNome operates a network of more than 30 fee-for-service vendors including contract manufacturers, CROs, CDMOs, analytics providers, and regulatory consultants. All contracts are structured fee-for-service with right of reference and escrow provisions, ensuring families/patient entities own all work product and can switch operators without regulatory restart.
  • Kizuna FoundationcoreStrategic or Co-development PartnerThe founder Stevie Ringel founded the Kizuna Foundation (a 501(c)(3)) to develop a novel gene therapy for his own rare retinal disease before starting Nome. The foundation's work informs Nome's model and the KIZ-mutation retinitis pigmentosa gene therapy program represents an early proof case for Nome's evaluation approach.
  • N=1 CollaborativeminorStrategic or Co-development PartnerWinston Yan, President of the N=1 Collaborative, serves as an advisor to Nome. The N=1 Collaborative (past 2,000 members) is a key organization advancing individualized ASO and gene therapy. This advisory relationship connects Nome to the broader N-of-1 therapy ecosystem.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Nome Bio competitors and assessment

Company assessment

Broad incumbents

  • Tempus AI: AI-powered precision medicine company with extensive multimodal data, sequencing, and clinical decision support capabilities. Overlapping AI-health positioning with much broader scale and enterprise contracts across pharma and providers.
  • GeneDx: Clinical genomics company focused on rare disease diagnosis and whole exome/genome sequencing. Operates upstream of Nome's workflow — feeds the genetic diagnoses that create Nome's customer pipeline — and represents a potential strategic partner or channel.
  • Recursion Pharmaceuticals: AI-native drug discovery company combining high-throughput biology with machine learning to identify treatments across multiple disease areas. Comparable AI-for-drug-discovery positioning, but operates a broad pipeline model rather than individualized therapy services.
  • Charles River Laboratories: Large CRO/CDMO providing preclinical, clinical, and manufacturing services to the rare disease and broader biotech market. Comparable as one of the vendor types Nome orchestrates; could plausibly build or acquire an n-of-1 coordination layer.
  • Deep Genomics: AI-driven RNA therapeutics company using machine learning to identify novel genetic medicines. Comparable AI + genetic medicine positioning, but a pipeline-based biotech rather than a service platform; an advisor (former SVP Research Operations) previously worked there.

Emerging players

  • Dyno Therapeutics: AI company designing AAV capsid delivery vectors for gene therapy, including brain-targeting variants. Referenced in Nome's content; operates as a delivery-technology enabler that could integrate into Nome-coordinated programs.
  • Creyon Bio: AI-driven oligonucleotide therapeutics company engineering ASOs and siRNAs with safety/efficacy predictively modeled. Comparable AI + genetic medicine focus at the modality level; could be a vendor or partner within Nome's ecosystem.

Direct peers

  • COMBINEDBrain: Nonprofit consortium representing 65+ rare genetic neurodevelopmental disorder advocacy groups and operating a centralized biorepository. Both strategic partner and peer — overlapping patient access mission in the rare pediatric neurodevelopmental space, with biorepository and cell-banking infrastructure Nome relies on.
  • N=1 Collaborative: Mission-driven organization advancing individualized ASO and gene therapy development, with 2,000+ members across the n-of-1 ecosystem. Directly comparable mission; an advisor to Nome sits on its leadership. Operates as a community/research consortium rather than a commercial service.
  • n-Lorem Foundation: Nonprofit providing individualized antisense oligonucleotide (ASO) therapies to patients with ultra-rare genetic diseases at no cost. Most direct peer — also a free, individualized genetic therapy access program for n-of-1 patients, though non-commercial and ASO-only versus Nome's multi-modality commercial model.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Nome Bio social profiles

Digital presence

Nome Bio compliance and trust

Trust signal

Compliance2 records

Nome Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nome Bio leadership team

Management profile

Number of profiles

Profiles3 records

Nome Bio funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nome Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nome Bio

What does Nome Bio do?

Nome provides genetic medicine development as a service for rare disease families, patient foundations, and health systems. Using an AI platform combined with human expert review, the company delivers a free Initial Assessment Report evaluating personalized therapy options for a patient's specific mutation, a clinician-facing Provider Brief with mechanism-level rationale, and end-to-end Therapeutic Development Programs that coordinate 30+ vendors across the full lifecycle from diagnosis through FDA pathways to clinical execution. Programs are structured as fee-for-service with no royalties or equity taken from families, and IP is held by the patient or family from day one.

Is Nome Bio a public or private company?

Nome Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Nome Bio founded?

Nome Bio was founded in 2025. It employs 1 to 10 people.

Where is Nome Bio based?

Nome Bio is headquartered in San Diego, United States, in the North America region.

How does Nome Bio make money?

Three revenue lines are on record. Free Initial Genetic Assessment is the primary driver. The others are fee-for-Service Therapeutic Development Programs and provider Platform Access.

Who are Nome Bio's main competitors?

Broad incumbents on record are Tempus AI, GeneDx, Recursion Pharmaceuticals, Charles River Laboratories and Deep Genomics. Emerging players are Dyno Therapeutics and Creyon Bio. Direct peers are COMBINEDBrain, N=1 Collaborative and n-Lorem Foundation.

Does Nome Bio have an API?

No public API is recorded for Nome Bio.

What industry is Nome Bio in?

Nome Bio's product category is Personalized Genetic Medicine Services. Its primary akta.pro industry code is HLAIAIAA, Genetic & Genomic Rare Disease Therapeutics, with a secondary code of HLAAALAD, Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics). Its NAICS code is 5417 and its SIC code is 8000.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals